Insider Selling: Bioventus Inc. (NYSE:BVS) CFO Sells $66,214.62 in Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 6,498 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $66,214.62. Following the transaction, the chief financial officer now owns 118,817 shares of the company’s stock, valued at approximately $1,210,745.23. This represents a 5.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Mark Leonard Singleton also recently made the following trade(s):

• On Monday, December 23rd, Mark Leonard Singleton sold 10,733 shares of Bioventus stock. The stock was sold at an average price of $10.53, for a total transaction of $113,018.49.

Bioventus Stock Up 0.6 %

Bioventus stock opened at $10.01 on Friday. The stock has a market cap of $812.31 million, a P/E ratio of -16.41 and a beta of 0.85. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a twelve month low of $3.90 and a twelve month high of $14.38. The company’s 50-day moving average price is $10.32 and its two-hundred day moving average price is $10.86.

Analyst Upgrades and Downgrades

BVS has been the subject of a number of recent research reports. Canaccord Genuity Group increased their price objective on shares of Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. JPMorgan Chase & Co. upgraded shares of Bioventus from an “underweight” rating to a “neutral” rating and increased their price objective for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Institutional Trading of Bioventus

Several large investors have recently made changes to their positions in BVS. CWM LLC bought a new position in Bioventus during the third quarter worth $89,000. Allspring Global Investments Holdings LLC purchased a new position in Bioventus during the third quarter worth about $286,000. Olympiad Research LP purchased a new position in Bioventus during the third quarter worth about $251,000. Principal Financial Group Inc. purchased a new position in Bioventus in the third quarter valued at about $210,000. Finally, Covestor Ltd purchased a new position in Bioventus in the third quarter valued at about $69,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.